Wolverine Stack (BPC-157 + TB-500): What the Evidence Shows

Key takeaways

"Wolverine stack" is a marketing name for BPC-157 combined with TB-500, sold as separate vials or a blend.

Neither compound is FDA-approved; FDA lists both among bulk substances that may present significant safety risks in compounding.

Evidence is mostly animal research. No published trial has tested the two together in people.

Both are prohibited at all times by the World Anti-Doping Agency.

“Wolverine stack” is what vendors and forums call BPC-157 taken together with TB-500, sold either as two vials or as a single blended vial. The name promises fast healing. This page sets out what is actually known about each half and about the pair.

The two components

	BPC-157	TB-500
What it is	15-amino-acid synthetic peptide derived from a protein in gastric juice	Synthetic peptide based on the active region of thymosin beta-4
FDA status	Not approved; FDA Category 2 (safety concerns in compounding)	Not approved; FDA Category 2
Evidence	Mostly rodent injury models; small human case series	Mostly animal and cell studies of thymosin beta-4
Sport	WADA prohibited	WADA prohibited

Profiles with research counts and trial records: BPC-157 and TB-500.

What the research shows

For BPC-157, a 2025 systematic review in orthopedic sports medicine found the literature dominated by animal studies, with very limited human data. The best-known human report is a 2021 retrospective series of knee-pain patients given intra-articular injections, without a control group. TB-500 studies are largely about thymosin beta-4 itself, in animal models of heart, eye and wound injury; TB-500 is a fragment, and fragment and parent molecule are not interchangeable.

No published study has tested BPC-157 and TB-500 together. Any claim that the pair works better than either alone is extrapolation.

Regulation

FDA has placed both substances in Category 2 of bulk drug substances nominated for compounding, which signals significant safety concerns such as immunogenicity and impurities. An FDA advisory committee voted in July 2026 to recommend BPC-157 for the 503A list, but FDA has not acted on that advice; see the BPC-157 advisory vote and are peptides legal?. Products sold as “research use only” are not for human use; see what research use only means.

Blends

A blended vial fixes the ratio between components, so neither can be adjusted alone, and the label figure for each component is only as reliable as the seller’s testing. How the arithmetic works for any blend is explained on our blends and stacks page; what a certificate of analysis should show is in how to read a COA.

Dosing

No FDA label or published human trial defines a dose of BPC-157, TB-500 or the combination, so we do not publish one.

Frequently asked questions

What is the wolverine stack?

A combination of two research peptides, BPC-157 and TB-500 (a fragment of thymosin beta-4), marketed for injury recovery. The name is a sales term, not a medical one.

Is the wolverine stack FDA-approved?

No. Neither BPC-157 nor TB-500 is an approved drug, and FDA lists both in its Category 2 of bulk drug substances that may present significant safety risks in compounding.

Does the wolverine stack work?

There is no human trial of the combination. BPC-157 research is largely in rodents, with a handful of small human case series; TB-500 is a synthetic fragment of thymosin beta-4, whose studies are mostly in animals and cells.

Is the wolverine stack legal in sport?

No. WADA prohibits BPC-157 and thymosin beta-4 and its fragments, including TB-500, in and out of competition.

What dose is used in the wolverine stack?

No dose has been established by an FDA label or a published human trial, so we do not publish one. Online protocols are not evidence.

The "wolverine stack": BPC-157 and TB-500, checked against the evidence